1. Catalogs
  2. GEA Tiromat Packaging - GEA Food Solutions Germany
  3. Pharmaceutical-Continuous-Processing-for-oral-solid-dosage-forms-2

Pharmaceutical-Continuous-Processing-for-oral-solid-dosage-forms-2

Pharmaceutical-Continuous-Processing-for-oral-solid-dosage-forms-2
1 / 42 PagesView full catalog

Pharmaceutical-Continuous-Processing-for-oral-solid-dosage-forms-2

Product catalog summary
Introduction to Continuous Processing
Continuous processing in pharmaceutical manufacturing offers a more efficient, agile, and flexible approach compared to traditional batch processes. It enhances product quality, reduces costs, and minimizes waste, making it a preferred choice for many leading pharmaceutical companies.
Advantages of Continuous Manufacturing (CM)
  • Improved efficiency and flexibility in production.
  • Consistent and reliable tablet production with reduced resource usage.
  • Enhanced drug safety and reduced industrial footprint.
  • Facilitates faster product development and market entry.
GEA's Role and ConsiGma® Technology
GEA has pioneered continuous manufacturing with its ConsiGma® platform, which integrates various processes from powder dosing to tablet coating. This technology supports a seamless transition from batch to continuous production, offering significant operational efficiencies and environmental benefits.
Key Features of ConsiGma®
  • Incorporates Six Sigma principles for quality control.
  • Reduces scale-up risks and costs with real-time release and online measurement.
  • Offers flexible batch sizes and reduces energy costs per tablet.
Process Modules and Customization
GEA's continuous lines can be customized with various process modules, including powder dosing, dry blending, granulation, drying, tablet compression, and coating. Each module is designed to optimize specific stages of the manufacturing process.
Innovative Collaborations and PCMM Platform
In collaboration with Pfizer and G-Con, GEA developed the PCMM platform, a portable and modular manufacturing system that can be rapidly deployed and reconfigured, offering a flexible solution for drug production in various locations.
Conclusion
Continuous processing represents a significant shift in pharmaceutical manufacturing, offering numerous benefits over traditional methods. GEA's ConsiGma® technology and collaborative innovations like the PCMM platform are setting new standards in the industry, focusing on efficiency, quality, and patient-centric manufacturing.
Overview: Vertex Pharmaceuticals, Inc. has collaborated with GEA to enhance their continuous manufacturing (CM) capabilities. They have invested in a multi-product development and launch rig (DLR) to produce multiple drug products continuously, from blending excipients to film-coated tablets, incorporating process analytical technology (PAT) for real-time release.
Continuous Manufacturing Process: The DLR integrates various processing steps into a continuous process, including wet granulation, fluidized bed drying, tablet compression, and film coating. It offers flexibility for multi-product use and includes options for dry granulation and direct compression. The process begins with blending the API with excipients, followed by granulation, drying, and compression, with real-time monitoring through PAT systems.
ConsiGma® Continuous Granulation and Compression Line: This platform replaces traditional batch processes with continuous operations, enhancing quality control and reducing costs. It supports fast process development and technology transfer, minimizing time to market and resource consumption. The system includes feeders, granulators, dryers, and tablet presses, with options for PAT integration and solvent processing upgrades.
Main Benefits: The continuous process reduces operational risks, requires fewer operators, and lowers costs. It offers higher equipment effectiveness, yield, and reduced waste, with up to 70% less GMP investment compared to batch systems.
ConsiGma® Direct Compression Lines: These lines streamline tablet production by integrating dosing, blending, and compression in one unit, eliminating intermediate storage. They offer fast product release, reduced operational risk, and lower costs per tablet, with compliance to QbD guidelines.
Continuous Tablet Coating: The ConsiGma® coater provides efficient tablet coating with improved heat and mass transfer, reducing coating time and material usage. It supports both batch and continuous operations, offering superior film-coat uniformity.
Continuous R&D Solutions: The ConsiGma® platform supports small-scale R&D with equipment that allows for quick and efficient process development. It enables direct transfer of process parameters to production scale, minimizing scale-up requirements.
Conclusion: The ConsiGma® technology offers a comprehensive solution for continuous pharmaceutical manufacturing, enhancing efficiency, reducing costs, and improving product quality through integrated and flexible processes.
Overview of Continuous Processing Technology
Continuous processing technology offers numerous advantages over traditional batch processing, including reduced space requirements, increased efficiency, and lower risk due to the elimination of scale-up or tech transfer to production-scale units. It allows for flexible batch sizes, fast changeovers, and user-friendly controls, making it a plug-and-play solution ready for immediate use. The process parameters are directly transferrable to production units, facilitating a seamless transition from development to manufacturing.
FDA's Adoption of GEA's Continuous Technology
The US FDA has embraced GEA's continuous manufacturing technology by acquiring a ConsiGma® 25/80 unit for research purposes. This unit, housed within the FDA's Office of Pharmaceutical Quality, supports the development and adoption of novel technologies to modernize pharmaceutical processing. The ConsiGma® 25/80 integrates Quality by Design (QbD) principles with Design of Experiments (DoE) to optimize process parameters efficiently, enhancing the understanding of continuous manufacturing.
ConsiGma® Dosing and Blending (DB)
The ConsiGma® DB is designed for efficient R&D, allowing exploration of formulations with 2-6 ingredients while minimizing the use of high-value APIs. It supports the development of direct compression formulations and preblending systems for continuous wet granulation lines. Key features include loss-in-weight feeders, continuous blenders, and options for PAT measurement and material handling systems.
Process Optimization and Digitalization
Process Analytical Technology (PAT) is utilized to monitor and control critical process parameters, ensuring product quality. The control system integrates SCADA, automation layers, and PAT tools to maintain process parameters within acceptable ranges. Advanced process controls (APCs) and multivariate controls are implemented to reduce variability and enhance process efficiency.
Customized Solutions and Industry Collaboration
GEA offers customized solutions for specific applications, considering factors like containment, cleaning, and sustainability. Collaborations with industry peers and academic institutions facilitate the adoption of continuous manufacturing by providing comprehensive support, from process development to equipment supply and control systems.
Conclusion
GEA's continuous processing technology, supported by collaborations with industry leaders, offers a transformative approach to pharmaceutical manufacturing. By overcoming technical barriers and optimizing processes, GEA enables faster product development, improved production economics, and increased manufacturing flexibility.
Continuous Processing Technologies: Continuous processing technologies are revolutionizing pharmaceutical development and manufacturing by enabling the quick and efficient delivery of customized drug quantities. GEA's ConsiGma® offers a state-of-the-art continuous manufacturing (CM) solution, emphasizing collaboration among companies to overcome challenges in adopting CM.
Collaborative Partnerships: GEA collaborates with companies to build partnerships with providers of complementary technologies, facilitating the implementation of continuous manufacturing. This collaboration aims to enhance services and infrastructure for customers.
Training and Development: GEA emphasizes the importance of training for the effective use of its equipment. The GEA Pharma Solids Center (GPSC) in Belgium offers regular training courses, including continuous processing, tableting technology seminars, and customized training. The GPSC provides a range of services such as process optimization, real-life simulations, and product development assistance.
Technological Offerings: The GPSC offers various technologies for testing, including continuous tableting lines and direct compression lines. It supports process development and refinement to enhance understanding and capability of GEA equipment.
Materials Handling: Contained materials handling is crucial for the efficiency and safety of continuous manufacturing lines. GEA provides solutions for materials handling challenges, emphasizing the importance of understanding the entire process to install the right solution.
Batch Processing: GEA offers a comprehensive range of batch technologies for oral solid dosage form production, including granulation and tableting technologies. The company provides solutions that integrate performance excellence with technological innovation.
Service and Support: GEA Service supports customers throughout the lifecycle of their plant and equipment, ensuring optimum performance and operational excellence. Services include maintenance, process optimization, and integration of automation and control solutions to enhance efficiency and reduce waste.
Commitment to Sustainability: GEA contributes to a sustainable future by reducing CO2 emissions, plastic use, and food waste in production. The company is listed on several sustainability indexes, reflecting its commitment to excellence, passion, integrity, and responsibility.
See more

Catalog excerpts

Pharmaceutical-Continuous-Processing-for-oral-solid-dosage-forms-2-1

Continuous Processing Solutions for Oral Solid Dosage Forms

 Open the catalog to page 1
Pharmaceutical-Continuous-Processing-for-oral-solid-dosage-forms-2-3

14 Years of Inspiration No other company has as much experience and done more to pioneer continuous manufacturing for the pharmaceutical industry Pharmaceutical manufacturers face CM is more efficient, agile and flexible many challenges when developing technology, offering more consistent and products and getting them to market in reliable tablet production with the reduced a timely, safe and cost-effective way. use and loss of resources such as precious APIs and raw materials, less stoppage time From formulating new molecular entities to and minimal manual intervention. Plus, improving the production...

 Open the catalog to page 3
Pharmaceutical-Continuous-Processing-for-oral-solid-dosage-forms-2-4

14 Years of Continuous Learning With a continuous line running at a customer’s site manufacturing concept. Thanks to our collaboration since 2007, GEA has, from the very beginning, led with complementary partners (universities, research the field with flexible development options that institutes and industrial partners, such as RCPE, facilitate the commercial manufacturing process and Siemens, UGent, etc.) we can offer a 360° approach enable greater process understanding to be achieved to continuous manufacturing, taking you from with smaller quantities of material. early development to commercial...

 Open the catalog to page 4
Pharmaceutical-Continuous-Processing-for-oral-solid-dosage-forms-2-5

CONTINUOUS PROCESSING ·

 Open the catalog to page 5
Pharmaceutical-Continuous-Processing-for-oral-solid-dosage-forms-2-7

Going Continuous The shift from batch to continuous production could represent one of the largest paradigm shifts in pharma processing since validation and qualification systems were introduced By focusing on quality during the whole product lifecycle — not • broad opportunity, ethical and generic, worldwide just “tested in” quality — and by understanding the capability • R&D: flexible batch size, no scale-up, fast DOE of your processes, sources of variability can be managed and any • reduced investment and running costs: easy to install, reduced associated risk can be eliminated. use of utilities,...

 Open the catalog to page 7
Pharmaceutical-Continuous-Processing-for-oral-solid-dosage-forms-2-8

Process Chain Powder Dosing Based on extensive process knowledge and continuous The accurate dosing of powdered excipients is a key and research, GEA offers a wide range of technical solutions critical technology for the continuous production of oral solid and process options to ensure the efficient mixing and dosage forms. As an enabler of its CM philosophy, and to meet blending of pharmaceutical powders and granules. market requirements, GEA, in an alliance with a supplier of extremely accurate load cells, offers a range of compact feeders Depending on the process, product and system set-up,...

 Open the catalog to page 8
Pharmaceutical-Continuous-Processing-for-oral-solid-dosage-forms-2-9

enhanced dual process control make them ideal For drying the wet granules, the dryer module – based on components of a continuous line allowing the tablet fluid-bed drying principles – splits the continuous flow of press to react to any variation in production rate, granules into packages, drying each of them in a separate without affecting the tablet quality. segment of the dryer and thereby guaranteeing plug-flow. When each segment is dry, it is emptied and transferred Tablet Coating to the evaluation module – where critical quality attributes Designed specifically to be an integral part of...

 Open the catalog to page 9
Pharmaceutical-Continuous-Processing-for-oral-solid-dosage-forms-2-11

MAKING CONTI REAL In collaboration with Pfizer and G-Con, GEA developed the PCMM (Portable, Continuous, Miniature and Modular manufacturing) platform, now operational at Pfizer’s facility in Groton, Connecticut, USA. Conceived, designed and built through a future-facing initiative between the three partners, the PCMM technology has at its center GEA’s state-of-the-art miniaturized and mobile ConsiGma® continuous oral solid dosage (OSD) pharmaceutical processing technology. Configurable for either direct blending and the compression of powder streams into tablets, or for wet granulation, drying,...

 Open the catalog to page 11
Pharmaceutical-Continuous-Processing-for-oral-solid-dosage-forms-2-12

Continuous Production Solutions Without the issues of start-up and/or shutdown waste, ConsiGma® provides maximum output in an energy efficient the ConsiGma® manufacturing platform is capable of way, has been tested using a wide variety of formulations and is continuously producing pharmaceutical products. This concept already being used by several large pharmaceutical companies, enables the use of the same system for both development and both ethical and generic research and manufacturing and production work without the need for scale-up; the centers worldwide. determining factor for the amount...

 Open the catalog to page 12
Pharmaceutical-Continuous-Processing-for-oral-solid-dosage-forms-2-13

ACCELERATING DRUG DEVELOPMENT To investigate continuous manufacturing (CM) and streamline, The process starts by blending the API with the excipients, Vertex Pharmaceuticals, Inc. partnered with GEA to enhance dispensed using loss-in-weight feeders into a continuous inline their existing technology and implement primary and backup blender. After initial blending, the machine can be configured CM processes. The company invested in a multi-product so that the blend flows into a twin-screw wet granulator (wet development and launch rig (DLR) to manufacture multiple granulation), a roller compactor...

 Open the catalog to page 13
Pharmaceutical-Continuous-Processing-for-oral-solid-dosage-forms-2-14

ConsiGma® Continuous Granulation and Compression (GC) Line Production-scale continuous high-shear granulation, drying and tableting The ConsiGma® GC is an innovative solid dosage production Standard Scope of Supply platform designed to achieve operational excellence in the • One loss-in-weight (LIW) feeder for preblended materials pharmaceutical manufacturing Industry. Raw materials are • Twin-screw granulator converted into final dosage forms in development, pilot, • Post-granulation sampling system clinical and production volumes using wet granulation in one • Liquid addition via peristaltic...

 Open the catalog to page 14
Pharmaceutical-Continuous-Processing-for-oral-solid-dosage-forms-2-15

Main Benefits • Horizontal or vertical layout • No scale-up or tech transfer risk • Post hoist for IBC feeding to LIW feeder • Reduced operational risk compared with batch • Preblending station with up to six • Minimal operators required feeders and two linear blenders • Lower risk of OOS product • One additional LIW feeder to add individual • Less operational cost (less space, no work raw materials into the granulator in progress, higher efficiency, etc.) • Diverter system to remove OOS material before • Less personal protective equipment (PPE) required and after granule conditioning unit •...

 Open the catalog to page 15
*Prices are pre-tax. They exclude delivery charges and customs duties and do not include additional charges for installation or activation options. Prices are indicative only and may vary by country, with changes to the cost of raw materials and exchange rates.